A Phenylthiazole Derivative Demonstrates Efficacy On Treatment of the Cryptococcosis &amp; Candidiasis in Animal Models

Sá, Nívea Pereira de; Lima, Caroline M; Santos, Julliana Ribeiro Alves; Costa, Marliete Carvalho; Barros, Patrícia Pimentel de; Junqueira, Juliana Campos; Vaz, Jéssica A.; Oliveira, Renata Barbosa de; Fuchs, Beth Burgwyn; Mylonakis, Eleftherios; Rosa, Carlos A.; Santos, Danielle Anjos dos; Johann, Susana

doi:10.4155/fsoa-2018-0001

Cited by 16 publications

(18 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides the numerous advantages previously described, G. mellonella proves to be very reliable even when compared to other invertebrate models [28,29], as demonstrated in two studies of S. aureus methicillin resistance, where the survival rate of the larger wax larvae was comparable to that of the nematode C. elegans [79,93]. Furthermore, despite the large evolutionary differences between insects and mammals, the results obtained by G. mellonella are comparable to those obtained with mice [4,48,66,111,112].…”

Section: Discussionmentioning

confidence: 73%

Galleria mellonella as a consolidated in vivo model hosts: New developments in antibacterial strategies and novel drug testing

et al. 2019

View full text Add to dashboard Cite

A greater ethical conscience, new global rules and a modified perception of ethical consciousness entail a more rigorous control on utilizations of vertebrates for in vivo studies. To cope with this new scenario, numerous alternatives to rodents have been proposed. Among these, the greater wax moth Galleria mellonella had a preponderant role, especially in the microbiological field, as demonstrated by the growing number of recent scientific publications. The reasons for its success must be sought in its peculiar characteristics such as the innate immune response mechanisms and the ability to grow at a temperature of 37°C. This review aims to describe the most relevant features of G. mellonella in microbiology, highlighting the most recent and relevant research on antibacterial strategies, novel drug tests and toxicological studies. Although solutions for some limitations are required, G. mellonella has all the necessary host features to be a consolidated in vivo model host.

show abstract

Section: Discussionmentioning

confidence: 73%

Galleria mellonella as a consolidated in vivo model hosts: New developments in antibacterial strategies and novel drug testing

et al. 2019

View full text Add to dashboard Cite

show abstract

“…, Cryptococcus spp. [32,33,[45][46][47][48][49][50][51], Aspergillus spp. [13,29,35,[52][53][54][55][56][57][58][59][60][61], Mucorales [62][63][64], Madurella mycetomatis [65][66][67], and other fungal agents [68][69][70].…”

Section: Evaluation Of Antifungal Efficacy In Galleria Mellonellamentioning

confidence: 99%

“…The genus Candida has been extensively studied in the G. mellonella model especially for the evaluation of virulence and antifungal efficacy [10,71,72]. G. mellonella was used to test the efficacy of different antifungal compounds against Candida yeasts including conventional antifungal drugs [13][14][15][16][17][18][19][20][21][22][23], new drugs [25][26][27][30][31][32]34] or non-antifungal compounds in a repurposing perspective [24,28,29,33]. Antifungal combinations against Candida spp.…”

Section: Candida Sppmentioning

confidence: 99%

“…Several drugs, such as atorvastatin, a cholesterol-lowering agent [24], miltefosine, an anti-leishmanial drug [33], miramistin, an antiseptic [29], and pilocarpine, a muscarinic agonist [28] were evaluated in a repurposing perspective. In other instances, new synthetic compounds or natural products were tested in vivo in the model [25][26][27][30][31][32]34]. It must be noticed that in all cases, larvae were infected with C. albicans.…”

Section: New Drugsmentioning

confidence: 99%

“…CHT increased survival for C. gattii and C. neoformans infected larvae. Correlation with a murine model [32] C. neoformans C. gattii In what is probably the first study of antifungal efficacy in G. mellonella, Mylonakis et al [47] used the conventional antifungal agents for the treatment of Cryptococcus infection. The administration of amphotericin B or flucytosine was effective in reducing mortality compared to untreated controls.…”

Section: Cryptococcus Sppmentioning

confidence: 99%

See 2 more Smart Citations

Galleria mellonella for the Evaluation of Antifungal Efficacy against Medically Important Fungi, a Narrative Review

et al. 2020

View full text Add to dashboard Cite

The treatment of invasive fungal infections remains challenging and the emergence of new fungal pathogens as well as the development of resistance to the main antifungal drugs highlight the need for novel therapeutic strategies. Although in vitro antifungal susceptibility testing has come of age, the proper evaluation of therapeutic efficacy of current or new antifungals is dependent on the use of animal models. Mammalian models, particularly using rodents, are the cornerstone for evaluation of antifungal efficacy, but are limited by increased costs and ethical considerations. To circumvent these limitations, alternative invertebrate models, such as Galleria mellonella, have been developed. Larvae of G. mellonella have been widely used for testing virulence of fungi and more recently have proven useful for evaluation of antifungal efficacy. This model is suitable for infection by different fungal pathogens including yeasts (Candida, Cryptococcus, Trichosporon) and filamentous fungi (Aspergillus, Mucorales). Antifungal efficacy may be easily estimated by fungal burden or mortality rate in infected and treated larvae. The aim of the present review is to summarize the actual data about the use of G. mellonella for testing the in vivo efficacy of licensed antifungal drugs, new drugs, and combination therapies.

show abstract

The Brazilian compound library (BraCoLi) database: a repository of chemical and biological information for drug design

et al. 2022

View full text Add to dashboard Cite

The Brazilian Compound Library (BraCoLi) is a novel open access and manually curated electronic library of compounds developed by Brazilian research groups to support further computer-aided drug design works. Herein, the first version of the database is described comprising 1,176 compounds. Also, the chemical diversity and drug-like profiles of BraCoLi were defined to analyze its chemical space. A significant amount of the compounds fitted Lipinski and Veber's rules, alongside other drug-likeness properties. A comparison using principal component analysis showed that BraCoLi is similar to other databases (FDA-approved drugs and NuBBEDB) regarding structural and physicochemical patterns. Furthermore, a scaffold analysis showed that BraCoLi presents several privileged chemical skeletons with great diversity. Despite the similar distribution in the structural and physicochemical spaces, similarity analysis indicated that compounds present in the BraCoLi are generally different from the two other databases showing an interesting innovative aspect, which is a desirable feature for novel drug design purposes.

show abstract

A Phenylthiazole Derivative Demonstrates Efficacy On Treatment of the Cryptococcosis & Candidiasis in Animal Models

Cited by 16 publications

References 38 publications

Galleria mellonella as a consolidated in vivo model hosts: New developments in antibacterial strategies and novel drug testing

Galleria mellonella as a consolidated in vivo model hosts: New developments in antibacterial strategies and novel drug testing

Galleria mellonella for the Evaluation of Antifungal Efficacy against Medically Important Fungi, a Narrative Review

The Brazilian compound library (BraCoLi) database: a repository of chemical and biological information for drug design

Contact Info

Product

Resources

About